Research led by the CDC and conducted at seven academic pediatric medical centers in the United States finds nirsevimab (sold ...
In a new study, the RSV drug nirsevimab was 93% effective at preventing young children from being hospitalized for the ...
Effectiveness of Nirsevimab for Respiratory Syncytial Virus in Infants and Young Children,” published in the November 2024 ...
New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...
The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...
Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...
This analysis documented the continued high burden of medically attended respiratory syncytial virus (RSV)-associated acute respiratory illness among young children in the U.S. Nirsevimab and maternal ...
Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiven ...
A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...
University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...
Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...
The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...